2011至2020年择期全膝关节置换术中静脉血栓栓塞症与药物预防使用趋势
该回顾性研究利用全付费方理赔数据集,纳入2011至2020年间因骨关节炎行择期全膝关节置换术的1,263,351例患者,分析术后90天内静脉血栓栓塞症发生率及药物预防使用变化。结果显示静脉血栓栓塞症率从2011年2.9%降至2020年1.8%,阿司匹林使用从5.9%升至53.2%,抗凝药使用从94.1%降至46.8%。
要点
- 静脉血栓栓塞症率从2011年2.9%降至2020年1.8%,深静脉血栓从2.0%降至1.3%,肺栓塞从1.1%降至0.6%。
- 术后阿司匹林使用从2011年5.9%升至2020年53.2%,抗凝药使用从94.1%降至46.8%。
- 直接Xa因子抑制剂使用从4.6%增至69.7%,为抗凝药中增幅最大。
核心结论
- 自2011年以来,全膝关节置换术后静脉血栓栓塞症的发生率和经济负担显著下降。
- 术后药物预防呈现阿司匹林和直接口服抗凝药使用增加的趋势。
研究设计与样本
- 回顾性研究,使用大型全付费方理赔数据集,纳入2011至2020年间因骨关节炎行择期全膝关节置换术的患者共1,263,351例。
- 采用线性回归和累积年增长率分析时间趋势,并采用多变量逻辑回归校正年龄和合并症的影响。
主要发现
- 静脉血栓栓塞症率从2011年2.9%降至2020年1.8%,深静脉血栓率从2.0%降至1.3%,肺栓塞率从1.1%降至0.6%。
- 术后阿司匹林使用从2011年5.9%增至2020年53.2%,抗凝药使用从94.1%降至46.8%。
- 抗凝药中直接Xa因子抑制剂使用增幅最大,从4.6%增至69.7%。
- 全膝关节置换术后静脉血栓栓塞症的平均报销费用从2011年18,061美元降至2020年7,835美元。
关键数值与推荐
- 静脉血栓栓塞症定义为全膝关节置换术后90天内发生的深静脉血栓和肺栓塞。
- 骨关节炎指征行择期全膝关节置换术的患者纳入分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) is a feared complication of joint arthroplasty, leading to recent clinical practice guidelines aimed at VTE prevention and prophylaxis. However, limited studies have examined national changes in practice regarding chemoprophylaxis and the resultant changes in VTE rates. The purpose of this study was to identify: (1) the temporal trends in thrombotic complications; and (2) changes in chemoprophylaxis utilization in patients undergoing elective total knee arthroplasty (TKA). METHODS: A retrospective study was conducted using a large all-payer claims dataset. Patients who underwent osteoarthritis-indicated TKA between 2011 and 2020 were identified. Annual rates of VTE, including deep vein thrombosis and pulmonary embolism, within 90 days of TKA were determined. Utilization patterns for postoperative aspirin and anticoagulant medications were observed. Temporal trends were analyzed with linear regression and the calculation of the cumulative annual growth rate. Multivariable logistic regression was conducted to account for the effects of age and comorbidities. RESULTS: A total of 1,263,351 TKA patients were identified between 2011 and 2020. There were significant reductions in VTE rates (2.9% in 2011 to 1.8% in 2020), deep vein thrombosis rates (2.0% in 2011 to 1.3% in 2020), and pulmonary embolism rates (1.1% in 2011 to 0.6% in 2020). Postoperative utilization of aspirin increased from 5.9% in 2011 to 53.2% in 2020, whereas utilization of anticoagulants decreased from 94.1% in 2011 to 46.8% in 2020. Among anticoagulants, direct factor Xa inhibitors had the greatest increase in utilization (4.6 to 69.7%). The average reimbursement associated with VTE after TKA decreased from $18,061 in 2011 to $7,835 in 2020. CONCLUSIONS: The incidence rate and economic burden of VTE after TKA have significantly declined since 2011. There has been a trend toward increased aspirin and direct oral anticoagulant utilization for postoperative chemoprophylaxis. LEVEL OF EVIDENCE: Level III.
引用
- Chiu AK, Agarwal AR, Hussain N, et al. Trends in Venous Thromboembolism and Chemoprophylaxis Utilization in Elective Total Knee Arthroplasty From 2011 to 2020. J Arthroplasty. 2024. PMID: 38759821. doi:10.1016/j.arth.2024.05.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。